VivoSim Labs (VIVS) Non Operating Income (2011 - 2026)
VivoSim Labs (VIVS) posted quarterly Non Operating Income of -$2.6 million for Q1 2026, down 125.75% year-over-year from $10.0 million in Q1 2025, and down 4467.8% quarter-over-quarter from $59000.0 in Q4 2025.
VivoSim Labs (VIVS) Non Operating Income (2011 - 2026) Analysis & Trends
VivoSim Labs' Non Operating Income history runs 16 years deep, the most recent figure standing at -$2.6 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 125.75% year-over-year to -$2.6 million; the TTM figure through Mar 2026 stood at -$2.4 million (down 123.24% YoY), while the FY2026 annual figure was -$2.4 million, down 123.24% from the prior year.
- Non Operating Income for Q1 2026 stood at -$2.6 million, down from $59000.0 in the prior quarter.
- The five-year high for Non Operating Income was $10.0 million in Q1 2025, with the low at -$2.6 million in Q1 2026.
- The 5-year median for Non Operating Income is $59000.0 (2024), against an average of $509941.2.
- The sharpest annual moves came in 2025 and 2026: Non Operating Income soared 19519.61% in 2025, then slumped 125.75% in 2026.
- VivoSim Labs' Non Operating Income stood at $95000.0 in 2022, then slipped by 20.0% to $76000.0 in 2023, then tumbled by 72.37% to $21000.0 in 2024, then surged by 180.95% to $59000.0 in 2025, then plunged by 4467.8% to -$2.6 million in 2026.
- Business Quant data shows VIVS's Non Operating Income at -$2.6 million in Q1 2026, $59000.0 in Q4 2025, and $92000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | VivoSim Labs | 1.49 Mn | 1.49 Mn | - | 1.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.42 Mn |
| Mar 31, 2026 | -2.58 Mn |
| Dec 31, 2025 | 59,000.00 |
| Sep 30, 2025 | 92,000.00 |
| Jun 30, 2025 | 72,000.00 |
| Mar 31, 2025 | 10.01 Mn |
| Dec 31, 2024 | 21,000.00 |
| Sep 30, 2024 | 59,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 51,000.00 |
| Dec 31, 2023 | 76,000.00 |
| Sep 30, 2023 | 121,000.00 |
| Jun 30, 2023 | 169,000.00 |
| Mar 31, 2023 | 320,000.00 |
| Dec 31, 2022 | 95,000.00 |
| Sep 30, 2022 | 33,000.00 |
| Jun 30, 2022 | 26,000.00 |
| Mar 31, 2022 | 2,000.00 |
| Dec 31, 2021 | 2,000.00 |
| Sep 30, 2021 | 2,000.00 |